Corcept Therapeutics (CORT) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to -$421.7 million.
- Corcept Therapeutics' Enterprise Value fell 1087.12% to -$421.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$421.7 million, marking a year-over-year decrease of 1087.12%. This contributed to the annual value of -$383.3 million for FY2024, which is 410.43% down from last year.
- Corcept Therapeutics' Enterprise Value amounted to -$421.7 million in Q3 2025, which was down 1087.12% from -$342.2 million recorded in Q2 2025.
- In the past 5 years, Corcept Therapeutics' Enterprise Value registered a high of -$223.5 million during Q4 2021, and its lowest value of -$473.2 million during Q2 2024.
- For the 5-year period, Corcept Therapeutics' Enterprise Value averaged around -$376.7 million, with its median value being -$370.1 million (2022).
- In the last 5 years, Corcept Therapeutics' Enterprise Value surged by 4927.68% in 2021 and then plummeted by 9311.16% in 2022.
- Quarter analysis of 5 years shows Corcept Therapeutics' Enterprise Value stood at -$223.5 million in 2021, then crashed by 93.11% to -$431.7 million in 2022, then increased by 14.7% to -$368.2 million in 2023, then fell by 4.1% to -$383.3 million in 2024, then dropped by 10.0% to -$421.7 million in 2025.
- Its Enterprise Value stands at -$421.7 million for Q3 2025, versus -$342.2 million for Q2 2025 and -$322.8 million for Q1 2025.